Scienza e Tecnologia
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
The proceeds will be used to accelerate clinical development of best-in-class immunology programs and advance preclinical programs against novel drug targets with its prolific drug discovery engine.
The equity financing was led by venBio Partners alongside new investors, including Third Point, RTW Investments, LP, Janus Henderson Investors, Wellington Management, OrbiMed, Surveyor Capital (a Citadel company), Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA , Cormorant Asset Management, and participation from founding investor New Science Ventures. In connection with the financing, Richard Gaster and Aaron Royston of venBio Partners and Jigar Choksey of Third Point will be joining the Ventyx Board of Directors.
" " ."
Ventyx's internally discovered and wholly-owned portfolio of potent and selective small molecule drug candidates target multiple indications in the immunology space, including gastrointestinal and dermatological diseases. The company's pipeline combines the clinical stage programs of three companies founded by Raju Mohan and New Science Ventures:
In addition, the company is leveraging its world-class drug discovery platform to advance preclinical programs against other biologically relevant targets involved in difficult to treat inflammatory diseases and autoimmune disorders.
NSV is a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value. NSV invests in companies using fundamental, science-based innovations and backed by strong IP protection to address large unmet needs in Life Sciences and Information Technology sectors. We invest in early and mid-stage companies with a long-term view and support our companies through value inflection points to create scalable businesses and realize value. NSV is a founding investor in Ventyx Biosciences.
NSV was founded in 2004 and is based in New York, NY and London, UK and operates a Life Sciences incubator in San Diego, CA.
For more information please visit: www.newscienceventures.com
Ventyx Biosciences, Inc. is a clinical-stage biotechnology company advancing a broad pipeline of potent and selective small-molecule drug candidates to treat inflammatory diseases and autoimmune disorders. Ventyx Biosciences combines assets from three formerly independent, asset-centric companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting the NLRP3 inflammasome, and the original Ventyx Biosciences, targeting TYK2. The diversified portfolio in the newly formed joint entity includes best-in-class, highly differentiated clinical-stage programs and preclinical programs focused on high-value targets.
Ventyx is headquartered in Encinitas, California . For more information about Ventyx, please visit www.ventyxbio.com.
:
Citigate Dewe Rogerson
Sylvie Berrebi / Nathaniel Dahan PhD / Mark Swallow PhD
T: +44 (0)20 7638 9571
E: NSV@citigatedewerogerson.com